Headline News

 

GSK continued progress in oncology pipeline and portfolio with data presented at ESMO

Posted on September 14, 2021

Significant benefits for asthma patients in MANDALA and DENALI Phase III trials for fixed-dose combination of albuterol and budesonide

Posted on September 14, 2021

Sanofi update on Phase 3 study evaluating rilzabrutinib for the treatment of pemphigus

Posted on September 14, 2021

Healthcare Providers Believe According to New Multinational Survey, Immunotherapy Has Potential to Positively Impact Earlier-Stage Cancer Treatment Landscape Across Tumor Types

Posted on September 14, 2021

Gilead to Present New Data Reinforcing the Practice-changing Potential of Trodelvy at ESMO Congress 2021

Posted on September 14, 2021

Thermo Fisher Scientific to Expand Global Network of Single-Use Technology Manufacturing Sites

Posted on September 14, 2021

Significant Advances Across Industry-Leading mRNA Portfolio Announced by Moderna at 2021 R&D Day

Posted on September 14, 2021

mRNA for Moderna’s COVID-19 Vaccine to be Manufactured by Resilience

Posted on September 14, 2021

Janssen Demonstrates at ESMO Annual Congress Commitment to Advancing Science and Innovation in the Treatment of Solid Tumo

Posted on September 08, 2021

Kadmon aquired by Sanofi to further strengthen growth of transplant business

Posted on September 08, 2021

GE Healthcare Unveils Next Gen Portable X-Ray System to Help Address Technologist Stress and Strain and Improve Efficiency

Posted on September 07, 2021

Novartis presents new findings at ERS reinforcing the efficacy of Enerzair® Breezhaler®, highlighting its digital companion, as well as showcasing commitment to low carbon footprint asthma solutions

Posted on September 07, 2021

Moderna Announces Submission of Data to European Medicines Agency for its COVID-19 Vaccine Booster

Posted on September 07, 2021

Thermo Fisher Scientific Awarded $192.5 Million U.S. Government Contract to Expand Domestic Pipette Tip Manufacturing

Posted on September 07, 2021

Takeda to Manufacture and Provide 150 Million Doses of Novavax’ COVID-19 Vaccine Candidate to the Government of Japan

Posted on September 07, 2021